Evaluation of Simplified Anti-Thrombotic Therapy for Coronary Fractional Flow Reserve (SMART-FFR)

NCT02384070 NA COMPLETED Results posted

Despite the routine use of procedural anti-coagulation and anti-platelet therapy for FFR calculation, no study has evaluated the optimal anti-thrombotic regimen in patients undergoing FFR. Therefore, the aim of the Evaluation of Simplified Anti-Thrombotic Therapy for Coronary Fractional Flow Reserve (SMART-FFR) study was to evaluate the safety of using a simplified anti-thrombotic regimen with only upstream dual anti-platelet therapy (DAT) with aspirin and clopidogrel, compared with anticoagulation plus single- or- DAT therapy in patients with intermediate coronary artery stenosis undergoing FFR calculation during elective coronary angiography.

Details

Lead sponsor	Odessa Heart Institute
Phase	NA
Status	COMPLETED
Enrolment	300
Start date	2009-01
Completion	2014-12

Conditions

• Coronary Artery Disease

Interventions

• FFR
• Aspirin
• Clopidogrel
• Bivalirudin

Primary outcomes

• Thrombotic Complications — Hospital Stay and after 30 days post PCI